Stimulation of neutralizing antibodies to human immunodeficiency virus type 1 in three strains of mice immunized with a 22 amino acid peptide of gp41 expressed on the surface of a plant virus

By McLain L.   Durrani Z.   Wisniewski L.A.   Porta C.   Lomonossoff G.P.   Dimmock N.J.  

Vaccine, Vol. 14, Iss. 8, 1996-06 ,pp. : 799-810

Elsevier

Access to resources Recommend Favorite

Cross-clade neutralizing antibody production against human immunodeficiency virus type 1 clade E and B' strains by recombinant Mycobacterium bovis BCG-based candidate vaccine

By Chujoh Y.   Matsuo K.   Yoshizaki H.   Nakasatomi T.   Someya K.   Okamoto Y.   Naganawa S.   Haga S.   Yoshikura H.   Yamazaki A.   Yamazaki S.   Honda M.  

Vaccine, Vol. 20, Iss. 5, 2001-12 ,pp. : 797-804

Elsevier

Access to resources Recommend Favorite

Neutralizing antibodies against highly cytopathic Zairian human immunodeficiency type-1 virus (HIV-1) NDK are present in sera outside Africa

By Machado A.A.   Baknabua M.   Salaun D.   de Mareuil J.   Krciinak V.   MacGregor R.R.   Chermann J.-C.   Hirsch I.  

Vaccine, Vol. 13, Iss. 3, 1995-01 ,pp. : 321-325

Elsevier

Access to resources Recommend Favorite

Mucosal delivery of the human immunodeficiency virus-1 Tat protein in mice elicits systemic neutralizing antibodies, cytotoxic T lymphocytes and mucosal IgA

By Marinaro M.   Riccomi A.   Rappuoli R.   Pizza M.   Fiorelli V.   Tripiciano A.   Cafaro A.   Ensoli B.   De Magistris M.T.  

Vaccine, Vol. 21, Iss. 25, 2003-09 ,pp. : 3972-3981

Elsevier

Access to resources Recommend Favorite

Immunogenicity of DNA vaccines that direct the coincident expression of the 120 kDa glycoprotein of human immunodeficiency virus and the catalytic domain of cholera toxin

By Bagley K.C.   Shata M.T.   Onyabe D.Y.   DeVico A.L.   Fouts T.R.   Lewis G.K.   Hone D.M.  

Vaccine, Vol. 21, Iss. 23, 2003-07 ,pp. : 3335-3341

Elsevier

Access to resources Recommend Favorite